CYP19A1 and breast cancer: Another study suggests that the postmenopausal women who were treated with aromatase inhibitors and took topical estrogen treatment for the vaginal symptoms secondary to aromatase inhibitors showed poor systematic uptake indicating an indirect to decrease the suspicion of using this topical hormonal therapy and breast cancer recurrence [187].